Buy & Sell 10X Genomics Inc (TXG) – 10X Genomics Inc Price Today
Aura AI Summary
Key Stats
- $3.88BMarket Cap
- HealthSector
- -22.55%3M Drawdown
- $3.43BEnterprise Value
- -Dividend Yield
- 3% Buy | 97% SellTrading Activity
- 96 daysTypical Hold Time
10X Genomics Inc (TXG) is currently valued at a market capitalization of $3.88B, with an enterprise value of $3.43B. Over the past 52 weeks, 10X Genomics Inc has traded between a low of $10.42 and a high of $33.5, highlighting its annual price range. Over the past three months, 10X Genomics Inc has recorded a drawdown of -22.55%, reflecting recent price volatility. On average, investors hold 10X Genomics Inc for approximately 96 days, indicating typical investor behavior on the platform.
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Most Recent News
US government moves toward equity stakes in AI firms ahead of historic IPOs, reshaping investor ownership.
The US government is actively negotiating to take equity stakes in AI companies like OpenAI and Anthropic ahead of their planned IPOs, following a precedent set by its investment in Intel. This move aims to give the public a share in AI-driven growth...

Trulieve becomes first US cannabis stock listed on NYSE, signaling sector shift.
Trulieve Cannabis Corp. made history by becoming the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. This milestone was enabled by the Trump administration's reclassification of cannabis to Schedule III for m...

BIO-key flagged by Nasdaq for late 10-Q filing, risking its Nasdaq listing status.
BIO-key International, a leader in biometric authentication, received a Nasdaq notice for failing to file its quarterly 10-Q report on time for Q1 2026. Nasdaq's notice indicates the company's compliance with listing rules is under review, and a hear...
